EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY-NC-ND 4.0

Plasma Angiogenic Factors as Predictors of the Efficacy of Second-line Chemotherapy Combined with Angiogenesis Inhibitors in Metastatic Colorectal Cancer: Results From the GI-SCREEN CRC-Ukit Study

Satoshi Yuki, Kentaro Yamazaki, Yu Sunakawa, Hiroya Taniguchi, Hideaki Bando, Manabu Shiozawa, Tomohiro Nishina, Hisateru Yasui, Akiyoshi Kanazawa, Koji Ando, Yosuke Horita, Masahiro Goto und 9 weitere

Clinical Colorectal Cancer · 2024

DOI: 10.1016/j.clcc.2024.01.003 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Clinical Colorectal Cancer, 2024. Verfasst von Satoshi Yuki und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Hokkaido University Hospital, Sapporo, Japan. Electronic address: syuki@pop.med.hokudai.ac.jp. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Ramucirumab, Bevacizumab. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Japan Agency for Medical Research and Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The significance of angiogenic factors as predictors of second-line (2L) chemotherapy efficacy when combined with angiogenesis inhibitors for metastatic colorectal cancer (mCRC) remains unestablished. PATIENTS AND METHODS: In this multicenter prospective observational study, 17 angiogenic factors were analyzed in plasma samples collected at pretreatment and progression stages using a Luminex multiplex assay. Patients who received chemotherapy plus bevacizumab (BEV group), FOLFIRI plus ramucirumab (RAM group), or FOLFIRI plus aflibercept (AFL group) as the 2L treatment were included. Interactions between pretreatment and treatment groups for progression-free survival (PFS), overall survival (OS), and response rate (RR) were assessed using the propensity-score weighted Cox proportional hazards model. RESULTS: From February 2018 to September 2020, 283 patients were analyzed in the 2L cohort. A strong interaction was observed for PFS between BEV and RAM with HGF, sNeuropilin-1, sVEGFR-1, and sVEGFR-3. Interactions for RR between the BEV and RAM groups were observed for sNeuropilin-1 and sVEGFR-1. Contrarily, OS, PlGF, sVEGFR-1, and sVEGFR-3 differentiated the treatment effect between BEV and AFL. Plasma samples were evaluable for dynamic analysis in 203 patients. At progression, VEGF-A levels significantly decreased in the BEV group and increased in the RAM and AFL groups. CONCLUSION: The pretreatment plasma sVEGFR-1 and sVEGFR-3 levels could be predictive biomarkers for distinguishing BEV and RAM when combined with chemotherapy in 2L mCRC treatment. Based on the VEGF-A dynamics at progression, selecting RAM or AFL for patients with significantly elevated VEGF-A levels may be a 2L treatment strategy, with BEV considered for the third-line treatment. CLINICAL TRIAL NUMBER: UMIN000028616.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsRamucirumabBevacizumabFluorouracilAngiogenesis InhibitorsLeucovorinCamptothecinHumansMaleFemaleMiddle AgedAgedProspective StudiesRecombinant Fusion ProteinsAdultBiomarkers, TumorProgression-Free SurvivalReceptors, Vascular Endothelial Growth Factor

Stichwörter der Autor:innen

BevacizumabRamucirumabVEGF-A dynamicssVEGFR-1sVEGFR-3

Substanzen

RamucirumabBevacizumabFluorouracilAngiogenesis InhibitorsLeucovorinCamptothecinafliberceptRecombinant Fusion ProteinsBiomarkers, TumorReceptors, Vascular Endothelial Growth Factor

Autor:innen und Institutionen

  • Department of Gastroenterology and Hepatology, Hokkaido University Hospital, Sapporo, Japan. Electronic address: syuki@pop.med.hokudai.ac.jp.
  • Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Nagaizumi, Japan.
  • Department of Clinical Oncology, St. Marianna University School of Medicine, Kawasaki, Japan.
  • Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.
  • Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
  • Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan.

Förderung

  • Japan Agency for Medical Research and Development

Zitieren

APA

Yuki, S., Yamazaki, K., Sunakawa, Y., Taniguchi, H., Bando, H., Shiozawa, M., Nishina, T., Yasui, H., Kanazawa, A., Ando, K., Horita, Y., Goto, M., Okano, N., Moriwaki, T., Satoh, T., Tsuji, A., Yamashita, K., Asano, C., Abe, Y., …, & Yoshino, T. (2024). Plasma Angiogenic Factors as Predictors of the Efficacy of Second-line Chemotherapy Combined with Angiogenesis Inhibitors in Metastatic Colorectal Cancer: Results From the GI-SCREEN CRC-Ukit Study. Clinical Colorectal Cancer. https://doi.org/10.1016/j.clcc.2024.01.003

Vancouver

Yuki S, Yamazaki K, Sunakawa Y, Taniguchi H, Bando H, Shiozawa M, et al. Plasma Angiogenic Factors as Predictors of the Efficacy of Second-line Chemotherapy Combined with Angiogenesis Inhibitors in Metastatic Colorectal Cancer: Results From the GI-SCREEN CRC-Ukit Study. Clinical Colorectal Cancer. 2024. doi:10.1016/j.clcc.2024.01.003

BibTeX
@article{Yuki2024,
  author = {Yuki, Satoshi and Yamazaki, Kentaro and Sunakawa, Yu and Taniguchi, Hiroya and Bando, Hideaki and Shiozawa, Manabu and Nishina, Tomohiro and Yasui, Hisateru and Kanazawa, Akiyoshi and Ando, Koji and Horita, Yosuke and Goto, Masahiro and Okano, Naohiro and Moriwaki, Toshikazu and Satoh, Taroh and Tsuji, Akihito and Yamashita, Kaname and Asano, Chiharu and Abe, Yukiko and Nomura, Shogo and Yoshino, Takayuki},
  title = {Plasma Angiogenic Factors as Predictors of the Efficacy of Second-line Chemotherapy Combined with Angiogenesis Inhibitors in Metastatic Colorectal Cancer: Results From the GI-SCREEN CRC-Ukit Study},
  journal = {Clinical Colorectal Cancer},
  year = {2024},
  doi = {10.1016/j.clcc.2024.01.003}
}
Kostenlos starten →